Zennami Kenji, Sumitomo Makoto, Takahara Kiyoshi, Nukaya Takuhisa, Takenaka Masashi, Fukaya Kosuke, Ichino Manabu, Fukami Naohiko, Sasaki Hitomi, Kusaka Mamoru, Shiroki Ryoichi
Department of Urology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Department of Urology, Fujita Health University Okazaki Medical Center, Okazaki, Japan.
Int J Clin Oncol. 2021 Aug;26(8):1514-1523. doi: 10.1007/s10147-021-01939-3. Epub 2021 May 19.
To compare perioperative and long-term oncological outcomes and recurrence patterns between robot-assisted radical cystectomy with intra-corporeal urinary diversion (iRARC) and open radical cystectomy (ORC).
We retrospectively analyzed 177 bladder cancer patients who received iRARC or ORC at Fujita Health University between 2008 and 2020. Our primary endpoint was long-term oncological outcomes. As a secondary endpoint, we examined perioperative outcomes, complications, and recurrence patterns. These outcome measures were compared between the propensity score (PS)-matched cohorts.
PS-matched analysis resulted in 60 matched pairs from iRARC and ORC groups. The iRARC cohort was associated with significantly longer operative time (p = 0.02), lower estimated blood loss (p < 0.001), lower blood transfusion rate (p < 0.001), shorter length of hospital stay (p < 0.001), fewer overall complications (p = 0.03), and lower rate of postoperative ileus (p = 0.02). There was no statistically significant difference between iRARC and ORC in 5-year RFS (p = 0.46), CSS (p = 0.63), and OS (p = 0.71). RFS and CSS were also comparable, even in locally advanced (≥ cT3) disease. Multivariate analysis identified lymphovascular invasion as a robust predictor of RFS, CSS, and OS. The number of recurrence was similar between the groups, while extra-pelvic lymph nodes were more frequent in iRARC than that in ORC (22.7% vs. 7.7%).
iRARC has favorable perioperative outcomes, fewer complications, and comparable long-term survival outcomes, including locally advanced (≥ cT3) disease, compared to that in ORC. Our results need to be validated in prospective randomized clinical trials.
比较机器人辅助根治性膀胱切除术联合体内尿流改道术(iRARC)与开放性根治性膀胱切除术(ORC)的围手术期和长期肿瘤学结局以及复发模式。
我们回顾性分析了2008年至2020年间在藤田保健大学接受iRARC或ORC的177例膀胱癌患者。我们的主要终点是长期肿瘤学结局。作为次要终点,我们检查了围手术期结局、并发症和复发模式。这些结局指标在倾向评分(PS)匹配的队列之间进行比较。
PS匹配分析产生了来自iRARC组和ORC组的60对匹配对。iRARC队列的手术时间明显更长(p = 0.02),估计失血量更低(p < 0.001),输血率更低(p < 0.001),住院时间更短(p < 0.001),总体并发症更少(p = 0.03),术后肠梗阻发生率更低(p = 0.02)。iRARC和ORC在5年无复发生存率(RFS)(p = 0.46)、癌症特异性生存率(CSS)(p = 0.63)和总生存率(OS)(p = 0.71)方面没有统计学上的显著差异。即使在局部晚期(≥ cT3)疾病中,RFS和CSS也具有可比性。多变量分析确定血管淋巴管浸润是RFS、CSS和OS的有力预测指标。两组之间的复发次数相似,而iRARC组盆腔外淋巴结复发比ORC组更频繁(22.7%对7.7%)。
与ORC相比,iRARC具有良好的围手术期结局,并发症更少,长期生存结局相当,包括局部晚期(≥ cT3)疾病。我们的结果需要在前瞻性随机临床试验中得到验证。